MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

8.410 -0.720 (-7.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud ↗
 
Via Benzinga
News headline image
Where Aligos Therapeutics Stands With Analysts ↗
Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
News headline image
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Therapeutics's Return On Capital Employed Overview ↗
According to Benzinga Pro data, during Q2, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $3.69 million. Earnings were up 44.06%, but Aligos Therapeutics still reported an overall loss of $19.92... 
Via Benzinga
News headline image
Aligos Therapeutics Earnings Preview ↗
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
News headline image
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via GlobeNewswire
News headline image
Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate ↗
Aligos Therapeutics Inc (NASDAQ: ALGS) has  
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2022 ↗
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
News headline image
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study ↗
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201. 
Via Benzinga
News headline image
Aligos Therapeutics's Return On Capital Employed Insights ↗
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Preview: Aligos Therapeutics's Earnings ↗
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
News headline image
NASDAQ: ALGS Investor Notice: Investigation over Potential Wrongdoing at Aligos Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation on behalf of investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential wrongdoing at Aligos Therapeutics, Inc. was... 
Via SBWire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022 ↗
Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday. 
Via Benzinga
News headline image
Recap: Aligos Therapeutics Q4 Earnings ↗
Aligos Therapeutics (NASDAQ:ALGS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Aligos Therapeutics Earnings Preview ↗
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
Needham raised Airbnb, Inc. (NASDAQ: ABNB) price target from $210 to $220. Airbnb shares rose 3.1% to $185.70 in pre-market trading. 
Via Benzinga
News headline image
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
News headline image
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
News headline image
NASDAQ: ALGS Shareholder Notice: Investigation over Potential Securities Laws Violations by Aligos Therapeutics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 01/24/2022 -- An investigation for investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential securities laws violations by Aligos Therapeutics, Inc. was... 
Via SBWire
News headline image
ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story